Stock Events

Stock Events

Reneo Pharmaceuticals 

$18.20
26
+$0.90+5.2% Friday 20:00

Statistics

Day High
1.9
Day Low
1.68
52W High
82.9
52W Low
1.68
Volume
437,523
Avg. Volume
17,983
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6NovExpected
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Q3 2024
-1.6
-1.15
-0.7
-0.25
Expected EPS
-0.965
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
0Revenue
-77.39MNet Income

Analyst Ratings

17.50Average Price Target
The highest estimate is 21.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, competing in the rare disease space similar to Reneo Pharmaceuticals.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics is involved in the development of genetic medicines for rare diseases, directly competing with Reneo Pharmaceuticals' focus on rare genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, closely aligning with Reneo Pharmaceuticals' mission.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals works on RNAi therapeutics for the treatment of rare diseases, presenting a competitive approach to Reneo Pharmaceuticals' strategy.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, which places it in direct competition with Reneo Pharmaceuticals in the rare disease market.
PTC Therapeutics
PTCT
Mkt Cap5.98B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines for rare disorders, making it a competitor to Reneo Pharmaceuticals.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases, including rare diseases, which places it in competition with Reneo Pharmaceuticals' focus on genetic disorders.

About

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Show more...
CEO
Employees
8
Country
United States
ISIN
US75974E1038

Listings

XNAS
US
OKUR
BOATS
BOATS
OKUR.BOATS

0 Comments

Share your thoughts

FAQ

What is Reneo Pharmaceuticals stock price today?▼
The current price of RPHM is $18.20 USD — it has increased by +5.2% in the past 24 hours. Watch Reneo Pharmaceuticals stock price performance more closely on the chart.
What is Reneo Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Reneo Pharmaceuticals stocks are traded under the ticker RPHM.
What is Reneo Pharmaceuticals revenue for the last year?▼
Reneo Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Reneo Pharmaceuticals net income for the last year?▼
RPHM net income for the last year is -77.39M USD.
How many employees does Reneo Pharmaceuticals have?▼
As of August 21, 2026, the company has 8 employees.
In which sector is Reneo Pharmaceuticals located?▼
Reneo Pharmaceuticals operates in the Technology sector.
When did Reneo Pharmaceuticals complete a stock split?▼
The last stock split for Reneo Pharmaceuticals was on October 07, 2024 with a ratio of 1:10.